<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">TGFB2</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>TGFB2</td></tr>
<tr><td><strong>Full Name</strong></td><td>Transforming Growth Factor Beta 2</td></tr>
<tr><td><strong>Chromosome</strong></td><td>1q41</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td><a href="https://www.ncbi.nlm.nih.gov/gene/7048">7048</a></td></tr>
<tr><td><strong>OMIM</strong></td><td><a href="https://www.omim.org/entry/190220">190220</a></td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000192958</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P08123">P08123</a></td></tr>
<tr><td><strong>Gene Type</strong></td><td>Protein Coding</td></tr>
<tr><td><strong>Protein Length</strong></td><td>414 amino acids</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>47.7 kDa</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Glaucoma, Multiple Sclerosis, [Amyotrophic Lateral Sclerosis](/diseases/als)</td></tr>
</table>
</div>
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">TGFB2</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>TGFB2</td></tr>
<tr><td><strong>Full Name</strong></td><td>Transforming Growth Factor Beta 2</td></tr>
<tr><td><strong>Chromosome</strong></td><td>1q41</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td><a href="https://www.ncbi.nlm.nih.gov/gene/7048">7048</a></td></tr>
<tr><td><strong>OMIM</strong></td><td><a href="https://www.omim.org/entry/190220">190220</a></td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000192958</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P08123">P08123</a></td></tr>
<tr><td><strong>Gene Type</strong></td><td>Protein Coding</td></tr>
<tr><td><strong>Protein Length</strong></td><td>414 amino acids</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>47.7 kDa</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Glaucoma, Multiple Sclerosis, [Amyotrophic Lateral Sclerosis](/diseases/als)</td></tr>
</table>
</div>
TGFB2 (Transforming Growth Factor Beta 2) is a member of the TGF-beta superfamily of cytokines that plays critical roles in neural development, synaptic plasticity, and neuroinflammation regulation["@massague2012"][@krieglstein2012]. TGFB2 is widely expressed throughout the central nervous system, particularly in [neurons](/entities/neurons), [astrocytes](/entities/astrocytes), and [microglia](/entities/microglia), where it exerts both neuroprotective and immunomodulatory effects["@luo2017"].
The TGFB2 gene is located on chromosome 1q41 and spans approximately 23 kb. It consists of 7 exons encoding a 414-amino acid precursor protein. The gene is conserved across mammals, with orthologs identified in mouse, rat, zebrafish, and other vertebrates.
TGFB2 shows high evolutionary conservation, particularly in the N-terminal signal peptide directing secretion, the latency-associated peptide forming latent complex, and the C-terminal mature domain containing receptor-binding and biological activity.
The TGFB2 protein is synthesized as a precursor containing three domains. The signal peptide (residues 1-20) directs protein to the secretory pathway. The latency-associated peptide (LAP, residues 21-262) forms a latent complex with the mature peptide. The mature peptide (residues 263-414) is the biologically active cytokine[@shi2011].
TGFB2 signals through a heteromeric receptor complex including type II receptor (TGFBR2) binding TGFB2 with high affinity, type I receptor (TGFBR1/ALK5) recruited upon type II binding, and co-receptors including endoglin and betaglycan enhancing signaling. Upon receptor binding, TGFB2 activates canonical SMAD-dependent signaling[@derynck2014] where TGFB2 binds to TGFBR2, TGFBR2 recruits and phosphorylates TGFBR1, phosphorylated SMAD2/3 form complexes with SMAD4, and these complexes translocate to the nucleus to regulate gene transcription.
TGFB2 exerts powerful neuroprotective effects against various insults[@ruocco2005] including oxidative stress protection through upregulation of antioxidant enzymes, excitotoxicity mitigation through modulation of glutamate receptor signaling, apoptosis prevention through promotion of pro-survival gene expression, and axonal regeneration supporting neurite outgrowth after injury.
In the hippocampus, TGFB2 modulates both structural and functional plasticity[@fukuda2010][@wyss-coray2000] by enhancing long-term potentiation (LTP), promoting dendritic spine formation, improving learning and memory in transgenic mice, and supporting hippocampal neural stem cell function[@unger2018].
TGFB2 critically influences astrocyte function[@hamby2012] by modulating reactive astrogliosis, upregulating glutamate transporters, maintaining blood-brain barrier integrity, and regulating astrocyte-neuron metabolic coupling. As a key regulator of microglial activation states[@zhou2016][@butovsky2014], TGFB2 promotes transition from M1 to M2 phenotype, enhances phagocytosis, suppresses pro-inflammatory cytokine release, and supports microglial-mediated neuronal survival.
TGFB2 has been extensively studied in Alzheimer's disease pathogenesis[@zetterberg2016][@caraci2012]. Elevated TGFB2 levels in cerebrospinal fluid correlate with slower cognitive decline. TGFB2 promotes clearance of [amyloid-beta](/proteins/amyloid-beta) plaques through enhanced [microglia](/cell-types/microglia-neuroinflammation)-mediated phagocytosis[@tipping2019] and reduces [tau](/proteins/tau) pathology through modulation of kinase and phosphatase activities. Neuronal TGF-β signaling is essential for synaptic maintenance[@tesseur2006], with deficiency leading to age-dependent synaptic loss and cognitive decline.
In Parkinson's disease, TGFB2 exhibits neuroprotective effects[@siani2017][@chen2021] by protecting substantia nigra pars compacta neurons from 6-hydroxydopamine toxicity, supporting dopaminergic neuron survival in culture, and enhancing mitochondrial function. TGFB2 modulates [alpha-synuclein](/proteins/alpha-synuclein) aggregation and clearance[@khalil2022] by reducing alpha-synuclein phosphorylation and aggregation, enhancing autophagy-mediated clearance, and potentially reducing prion-like spreading.
TGFB2 is implicated in glaucoma with polymorphisms associated with primary open-angle glaucoma, multiple sclerosis where dysregulated TGF-beta signaling contributes to demyelination, and amyotrophic lateral sclerosis with altered TGFB2 expression in motor neurons and glia[@huang2020].
Given its neuroprotective properties, TGFB2 represents a potential therapeutic target through recombinant TGFB2 protein being investigated for neuroprotective applications, TGFB2 gene therapy using viral vector-mediated delivery in preclinical models, small molecule activators enhancing TGF-beta signaling, and cell-based therapies delivering TGFB2-expressing cells.
Several challenges must be addressed for clinical translation including blood-brain barrier penetration, dose-dependent effects (both neuroprotective and pathological at high levels), and systemic immunomodulatory effects. TGFB2 levels in cerebrospinal fluid may serve as disease progression marker, treatment response indicator, and prognostic biomarker for cognitive decline[@datlinger2017].
The following diagram shows the key molecular relationships involving TGFB2 Gene discovered through SciDEX knowledge graph analysis: